.jpeg)
2026-08-19 04:54:11
Resmetirom is approved for adults with non-cirrhotic NASH/MASH and moderate-to-severe liver fibrosis (F2–F3). It is not an antiviral agent for hepatitis B virus (HBV) and is not indicated for HBV-related cirrhosis. This article clarifies its mechanism of action and precise indication boundaries.
2026-08-19 04:40:21
Vemurafenib is an oral small-molecule BRAF kinase inhibitor designed to selectively target BRAF V600E and related mutations. This article explores its molecular mechanism, the essential role of BRAF genetic testing, and its positioning within precision oncology.
2026-08-19 04:31:49
Anagrelide and hydroxyurea are both widely used cytoreductive agents for essential thrombocythemia (ET). They differ in mechanism of action, vascular event prevention, adverse effect profiles, and long-term therapeutic positioning. This article provides a comprehensive comparison to guide individualized treatment decisions.
2026-08-18 04:30:05
SCEMBLIX (asciminib) is the first BCR-ABL1 myristoyl pocket allosteric inhibitor for chronic myeloid leukemia. This guide covers common side effects, dosing in hepatic/renal impairment, cardiovascular monitoring, drug interactions, and pregnancy risk.
2026-08-18 03:33:32
Sabril (vigabatrin) is an anti-seizure drug that irreversibly inhibits GABA transaminase to raise brain GABA levels. It is a key option for infantile spasms and refractory partial seizures, but carries a risk of permanent visual field loss requiring strict evaluation and regular ophthalmologic monitoring.
2026-08-18 03:25:17
In August 2026, the FDA approved Tauklarify (florquinitau F-18 injection, MK-6240), a radioactive diagnostic agent for PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease.
2026-08-17 07:50:41
Bristol Myers Squibb announced FDA approval of Zenbexus (iberdomide) in combination with the ZDd regimen for adults with multiple myeloma who have received at least one prior line of therapy — the first approved CELMoD therapy.
2026-08-17 06:53:57
While delivering its intended therapeutic benefits, elamipretide hydrochloride may induce adverse reactions predominantly manifesting as injection site responses and hypersensitivity risks. This article systematically outlines its safety profile, contraindications in special populations, and cold-chain storage requirements.
2026-08-17 06:41:29
A detailed overview of adverse reactions associated with dutasteride soft capsules for benign prostatic hyperplasia, covering sexual dysfunction, breast-related events, serious risks, and evidence-based mitigation approaches.
2026-08-17 06:24:52
Oral semaglutide tablets, developed by Novo Nordisk, are the world's first oral GLP-1 receptor agonist, indicated for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular events in high-risk patients.
2026-08-17 06:12:53
Sotorasib (brand name: Lumakras), developed by Amgen, is the world's first KRAS G12C inhibitor approved by the U.S. FDA in May 2021. It is indicated for adults with KRAS G12C-mutant advanced non-small cell lung cancer and metastatic colorectal cancer.
2026-08-14 03:20:41
This article systematically interprets Osimertinib, a core therapeutic drug for EGFR mutation-positive non-small cell lung cancer, covering pharmacological efficacy, common and serious adverse reactions, indications, usage and dosage, drug interactions and key points for special populations, providing a comprehensive reference for standardized clinical medication.
